CAR T‐Cell Therapy for Multiple Myeloma: A Clinical Practice‐Oriented Review

Abstract

The emergence of chimeric antigen receptor (CAR) T‐cell therapy has revolutionized the treatment of hematologic malignancies, including multiple myeloma (MM). Two BCMA‐directed CAR T‐cell products — idecabtagene vicleucel (ide‐cel) and ciltacabtagene autoleucel (cilta‐cel) — have received US Food and Drug Administration (FDA) approval for patients with relapsed/refractory MM who underwent four or more prior lines of therapy (including an immunomodulatory agent, a proteasome inhibitor, and an anti‐CD38 monoclonal antibody). Despite producing unprecedented response rates in an otherwise difficult to treat patient population, CAR T‐cell therapies are commonly associated with immune‐related adverse events (e.g., cytokine release syndrome and neurotoxicity), cytopenias, and infections. Moreover, many patients continue to exhibit relapse post‐treatment, with resistance mechanisms yet to be fully understood. Ongoing basic, translational, and clinical research efforts are poised to generate deeper insights into the optimal utilization of these therapies, improve their efficacy, minimize associated toxicity, and identify new target antigens in patients with MM.